By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



100 Cumming Center, Suite 151-B
Suite A225
Beverly  Massachusetts  01915  U.S.A.
Phone: 978-236-8717 Fax: 978-921-6564


Company News
Cellceutix (CTIX) Takes on Anonymous Blogger, Calls Mako Research's Actions "Criminal" 3/20/2017 6:13:40 AM
Cellceutix (CTIX) Provides Update On Developing P53 Drug Candidate Kevetrin As An Oral Anti-Cancer Agent 3/6/2017 8:38:42 AM
Cellceutix (CTIX) CEO Unhinged After Anonymous Short Trader's Attacks 1/23/2017 6:10:24 AM
Anonymous Short Trader Attacks Cellceutix (CTIX) Again 1/19/2017 5:59:44 AM
A Year After a Scathing Attack By a Short Seller, Cellceutix (CTIX) Eyes the Nasdaq and Big Investors 8/17/2016 5:47:56 AM
Cellceutix (CTIX) Files Motion To Dismiss Complaint Filed By The Rosen Law Firm 2/12/2016 9:24:52 AM
Cellceutix (CTIX) Meets With FDA For Phase 2 Clinical Trial Of Kevetrin For Ovarian Cancer 2/11/2016 10:19:45 AM
Cellceutix (CTIX) To Submit Special Protocol Assessment Request To FDA For Phase 3 Clinical Study Of Antibiotic Brilacidin For ABSSSI 2/9/2016 10:24:31 AM
Cellceutix (CTIX) Phase 2 Trial Of New Oral Treatment For Psoriasis Nearing Completion 1/25/2016 12:05:59 PM
Cellceutix (CTIX) Releases Data Used In Receiving FDA Orphan Drug Designation Of Kevetrin For Pancreatic Cancer 1/22/2016 10:44:30 AM